Benyi Li1, James Brantley Thrasher2, Paul Terranova3. 1. Department of Urology, University of Kansas Medical Center, Kansas City, KS. Electronic address: bli@kumc.edu. 2. Department of Urology, University of Kansas Medical Center, Kansas City, KS. 3. Department of Molecular and Integrative Physiology, University of Kansas Medical Center, Kansas City, KS; Department of Obstetrics and Gynecology, University of Kansas Medical Center, Kansas City, KS.
Abstract
OBJECTIVES: Prostate cancers are the frequently diagnosed cancers in men, and patients with metastatic disease only have 28% chance for 5-year survival. Patients with low-risk tumors are subjected to active surveillance, whereas high-risk cases are actively treated. Unfortunately, there is no cure for patients with late-stage disease. Glycogen synthase kinase-3 (GSK-3, α and β) is a protein serine/threonine kinase and has diverse cellular functions and numerous substrates. We sought to summarize all the studies done with GSK-3 in prostate cancers and to provide a prospective direction for future work. METHODS AND MATERIALS: A comprehensive search of the literature on the electronic databases PubMed was conducted for the subject terms of GSK-3 and prostate cancer. Gene mutation and expression information was extracted from Oncomine and COSMIC databases. Case reports were not included. RESULTS: Accumulating evidence indicates that GSK-3α is mainly expressed in low-risk prostate cancers and is related to hormone-dependent androgen receptor (AR)-mediated gene expression, whereas GSK-3β is mainly expressed in high-risk prostate cancers and is related to hormone-independent AR-mediated gene expression. GSK-3 has been demonstrated as a positive regulator in AR transactivation and prostate cancer growth independent of the Wnt/β-catenin pathway. Different types of GSK-3inhibitors including lithium show promising results in suppressing tumor growth in different animal models of prostate cancer. Importantly, clinical use of lithium is associated with reduced cancer incidence in psychiatric patients. CONCLUSIONS: Taken together, GSK-3 inhibition might be implicated in prostate cancer management as a preventive treatment.
OBJECTIVES:Prostate cancers are the frequently diagnosed cancers in men, and patients with metastatic disease only have 28% chance for 5-year survival. Patients with low-risk tumors are subjected to active surveillance, whereas high-risk cases are actively treated. Unfortunately, there is no cure for patients with late-stage disease. Glycogen synthase kinase-3 (GSK-3, α and β) is a protein serine/threonine kinase and has diverse cellular functions and numerous substrates. We sought to summarize all the studies done with GSK-3 in prostate cancers and to provide a prospective direction for future work. METHODS AND MATERIALS: A comprehensive search of the literature on the electronic databases PubMed was conducted for the subject terms of GSK-3 and prostate cancer. Gene mutation and expression information was extracted from Oncomine and COSMIC databases. Case reports were not included. RESULTS: Accumulating evidence indicates that GSK-3α is mainly expressed in low-risk prostate cancers and is related to hormone-dependent androgen receptor (AR)-mediated gene expression, whereas GSK-3β is mainly expressed in high-risk prostate cancers and is related to hormone-independent AR-mediated gene expression. GSK-3 has been demonstrated as a positive regulator in AR transactivation and prostate cancer growth independent of the Wnt/β-catenin pathway. Different types of GSK-3inhibitors including lithium show promising results in suppressing tumor growth in different animal models of prostate cancer. Importantly, clinical use of lithium is associated with reduced cancer incidence in psychiatricpatients. CONCLUSIONS: Taken together, GSK-3 inhibition might be implicated in prostate cancer management as a preventive treatment.
Authors: Frankie H F Lee; Oksana Kaidanovich-Beilin; John C Roder; James R Woodgett; Albert H C Wong Journal: Schizophr Res Date: 2011-04-17 Impact factor: 4.939
Authors: Gregory Carter; Kerrie Clover; Ben Britton; Alex J Mitchell; Martin White; Nicholas McLeod; Jim Denham; Sylvie D Lambert Journal: Cancer Treat Rev Date: 2014-11-13 Impact factor: 12.111
Authors: Andrei V Ougolkov; Martin E Fernandez-Zapico; Vladimir N Bilim; Thomas C Smyrk; Suresh T Chari; Daniel D Billadeau Journal: Clin Cancer Res Date: 2006-09-01 Impact factor: 12.531
Authors: Roberta Venè; Patrizia Larghero; Giuseppe Arena; Michael B Sporn; Adriana Albini; Francesca Tosetti Journal: Cancer Res Date: 2008-09-01 Impact factor: 12.701
Authors: Thomas R Salas; Jeri Kim; Funda Vakar-Lopez; Anita L Sabichi; Patricia Troncoso; Guido Jenster; Akira Kikuchi; Shao-Yong Chen; Lirim Shemshedini; Milind Suraokar; Christopher J Logothetis; John DiGiovanni; Scott M Lippman; David G Menter Journal: J Biol Chem Date: 2004-02-24 Impact factor: 5.157
Authors: Xiaoyu Wang; Catherine S Grasso; Kristina M Jordahl; Suzanne Kolb; Yaw A Nyame; Jonathan L Wright; Elaine A Ostrander; Dean A Troyer; Raymond Lance; Ziding Feng; James Y Dai; Janet L Stanford Journal: Prostate Cancer Prostatic Dis Date: 2020-02-18 Impact factor: 5.554
Authors: Hong Chen; Abul Fajol; Miriam Hoene; Bingbing Zhang; Erwin D Schleicher; Yun Lin; Carsten Calaminus; Bernd J Pichler; Cora Weigert; Hans U Häring; Florian Lang; Michael Föller Journal: Proc Natl Acad Sci U S A Date: 2016-05-02 Impact factor: 11.205
Authors: Sen Liu; Qiuyang Zhang; Chong Chen; Dongxia Ge; Yine Qu; Rongyi Chen; Yi-Ming Fan; Nan Li; Wendell W Tang; Wensheng Zhang; Kun Zhang; Alun R Wang; Brian G Rowan; Steven M Hill; Oliver Sartor; Asim B Abdel-Mageed; Leann Myers; Qishan Lin; Zongbing You Journal: Oncotarget Date: 2016-03-22